Loading briefing details...
Loading briefing details...
News Abstract
By: PointLine Media Research & Editorial Team
Topic:Business,Health,Science & Environment
May 27, 2026
Creative Biolabs has upgraded its next-generation sequencing (NGS) services, specifically adapting them for complex 3D biological models like organoids and spheroids. This enhancement aims to address difficulties in mapping the intricate genetic profiles of these advanced cellular structures.
The pharmaceutical sector often faces challenges in moving laboratory findings into clinical treatments. Traditional 2D cell cultures frequently fail to accurately represent human tissue architecture and genetic environments. Creative Biolabs' new approach provides comprehensive genomic mapping for patient-derived 3D models, improving their relevance for clinical studies.
The updated platform offers both whole-genome sequencing (WGS) for broad structural variant detection and high-depth targeted exome sequencing (WES) for focused disease-associated studies. Additionally, it incorporates advanced RNA sequencing to quantify real-time gene expression changes and analyze alternative splicing events, supporting discovery and validation stages.
The pharmaceutical industry continuously seeks more accurate methods to predict drug efficacy and toxicity before human trials. Traditional 2D cell cultures often lack the physiological complexity needed for reliable translation of research findings into clinical applications. Consequently, 3D biological models, such as organoids and spheroids, are increasingly adopted as they better mimic human tissue environments and disease states.
However, fully leveraging these complex models requires sophisticated tools to analyze their intricate genetic and molecular profiles. This move by Creative Biolabs reflects an industry-wide push to integrate advanced genomics with these sophisticated models, aiming to accelerate drug discovery and minimize late-stage failures by providing a more complete and accurate biological picture early in the research process.